[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336513-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336513-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","landscape-of-clinical-drug-development-of-adcs-used-for-the-pharmacotherapy-of-cancers-an-overview-of-clinical-trial-registry-data-from-2002-to-2022","Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers - an overview of clinical trial registry data from 2002 to 2022","","This study analyzes the landscape and characteristics of clinical trials of antibody-drug conjugates (ADCs) used for cancer pharmacotherapy, aiming to provide an industry reference for clinical ADC development. Sponsor-initiated cancer ADC trials were extracted from the Cite line Pharma Intelligence (Trialtrove) registry and assessed across multiple dimensions, including trial counts, phases, status, indications, and molecular targets. By Dec 31, 2022, 431 trials were identified across 47 indications, with targets that are relatively concentrated.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/landscape-of-clinical-drug-development-of-adcs-used-for-the-pharmacotherapy-of-cancers-an-overview-of-clinical-trial-registry-data-from-2002-to-2022/336513/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/landscape-of-clinical-drug-development-of-adcs-used-for-the-pharmacotherapy-of-cancers-an-overview-of-clinical-trial-registry-data-from-2002-to-2022/336513.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What sources were used to identify ADC cancer clinical trials?","Question",{"text":63,"@type":64},"Clinical trials were searched using the Cite line Pharma Intelligence (Trialtrove database), focusing on studies initiated by the sponsor.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many ADC-related cancer clinical trials were initiated by Dec 31, 2022?",{"text":68,"@type":64},"A total of 431 clinical trials were initiated to study ADCs used for the pharmacotherapy of cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study conclude about the development landscape of ADCs?",{"text":72,"@type":64},"The study concludes that ADCs are a hotspot in oncology clinical research, while the registered indications, targets, phases, and treatment lines are relatively concentrated at present.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336513,1790793254,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Zhou et al. BMC Cancer (2024) 24:898 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12652-5](https://doi.org/10.1186/s12885-024-12652-5)  \nRESEARCH Open Access  \nLandscape of clinical drug development  of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022  \nWenjing Zhou 1*†, Zhiyuan Xu2†, Shu Liu3†, Xiaohuan Lou 1, Pengcheng Liu4, Huali Xie5, Shuiyan Zhang6, Xi Liu 1, Baoshan Zhuo 1 and Hongbing Huang3*  \nAbstract  \nBackground To provide reference for clinical development of ADCs in the industry, we analyzed the landscape and characteristics of clinical trials about antibody-drug conjugates (ADCs) .  \nMethod Clinical trials to study ADCs used for the pharmacotherapy of cancers initiated by the sponsor were searched in the Cite line Pharma Intelligence (Trialtrove database), and the landscape and characteristics of these clinical trials were analyzed from multiple perspectives, such as the number, phases, status, indications, and targets of the clinical trials.  \nResult As of December 31, 2022, a total of 431 clinical trials have been initiated to study ADCs used for the pharmacotherapy of cancers, and the number of the last 10 years was 5.5 times as large as the first 11 years. These clinical trials involved 47 indications, including breast cancer, lymphoma (lymphoma, non-Hodgkin’s and lymphoma, Hodgkin’s), unspecified solid tumor, bladder cancer and lung cancer (lung, non-small cell cancer and lung, small cell cancer) . As for each of these five indications, 50 + clinical trials have been carried out, accounting for as high as 48. 50%(454/936) . ADCs involve 38 targets, which are relatively concentrated. Among them, ERBB2 (HER2) and TNFRSF8 (CD30) involve in 100 + registered clinical trials, and TNFRSF17 (BCMA), NECTIN4 and CD19 in 10 + trials. The clinical trials for these five targets account for 79 . 02%(354/448) of the total number. Up to 93 . 97%(405/431) of these clinical trials explored the correlation between biomarkers and efficacy. Up to 45 . 91%(292/636) of Lots (lines of treatment) applied in the clinical trials were the second line. Until December 31, 2022, 54 . 52%(235/431) of the clinical trials have been completed or terminated.  \n†Wenjing Zhou, Zhiyuan Xu and Shu Liu are Co-first authors.  \n*Correspondence: Wenjing Zhou [zhouwj@hku-szh.org](zhouwj@hku-szh.org)[ ](zhouwj@hku-szh.org)Hongbing Huang [huanghb@sysucc.org.cn](huanghb@sysucc.org.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.  \nZhou et al. BMC Cancer (2024) 24:898 Page 2 of 13  \nConclusion ADCs are a hotspot of research and development in oncology clinical trials, but the indications, targets, phases, and Lot that have been registered are seemingly relatively concentrated at present. This study provides a comprehen","cbCaipxEd6Phe6FA","https://ap.wps.com/l/cbCaipxEd6Phe6FA","pdf",3745792,13,"English","# Abstract\n# Background\n# Method\n# Result\n# Conclusion\n# Introduction\n## ADC components and rationale\n## Approved ADCs and indication/target coverage\n## Milestones in ADC development","[{\"question\":\"What sources were used to identify ADC cancer clinical trials?\",\"answer\":\"Clinical trials were searched using the Cite line Pharma Intelligence (Trialtrove database), focusing on studies initiated by the sponsor.\"},{\"question\":\"How many ADC-related cancer clinical trials were initiated by Dec 31, 2022?\",\"answer\":\"A total of 431 clinical trials were initiated to study ADCs used for the pharmacotherapy of cancers.\"},{\"question\":\"What did the study conclude about the development landscape of ADCs?\",\"answer\":\"The study concludes that ADCs are a hotspot in oncology clinical research, while the registered indications, targets, phases, and treatment lines are relatively concentrated at present.\"}]","Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers - an overview of clinical trial registry data from 2002 to 2022 | PDF",1790015391,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79c4087d7be38474111801431ecffda6.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b68d0abd55005b330a530a88d1cac3a.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/218daf2e0d80e01784339a8f83f666e1.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2a76fa6cf1581bc1a3180dc5169951d.webp",980,1306]